Med-Chemist

Med-Chemist : "Quintessential Medicinal Chemistry"

Showing posts with label Myelofibrosis. Show all posts
Showing posts with label Myelofibrosis. Show all posts
Saturday, January 25, 2020

FDA Approves Inrebic (fedratinib) for the Treatment of Patients With Myelofibrosis

›
Celgene Corporation (NASDAQ: CELG)  announced the U.S. Food and Drug Administration (FDA) approval of  Inrebic (fedratinib) for the ...
Wednesday, May 8, 2019

U.S. FDA Grants Priority Review for Fedratinib New Drug Application in Myelofibrosis

›
Celgene Corporation (NASDAQ:CELG)   announced the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application ...
Wednesday, December 14, 2011

Ruxolinitib reduces spleen size by 35% in patients with myelofibrosis

›
In continuation of my ruxolinitib In a major advance in treatment, a multicenter study found that ruxolinitib did a better job than off-...
Monday, August 8, 2011

FDA Accepts NDA Filing for Ruxolitinib as a Treatment for Myelofibrosis

›
FDA Accepts NDA Filing for Ruxolitinib as a Treatment for Myelofibrosis
›
Home
View web version

Contributors

  • Dr. Umesh..
  • https://www.med-chemist.com
Powered by Blogger.